Graduate Program in Health Sciences (Ppgcsa), Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
Department of Pharmacy, Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
Expert Opin Drug Deliv. 2021 Nov;18(11):1577-1587. doi: 10.1080/17425247.2021.1952978. Epub 2021 Jul 19.
Cannabidiol (CBD), a phytocannabinoid from , has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective.
This review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use.
Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders.
大麻二酚（CBD）是一种来自大麻的植物大麻素，具有多种治疗特性。然而，其高亲脂性、代谢和不稳定性会降低其生物利用度，并限制其在临床环境中的转化应用。已经评估了几种先进的药物传递系统（ADDS）作为 CBD 的载体，以克服这些缺点。这些系统可以改善 CBD 的溶解特性，保护其免受代谢作用，并产生特定部位的释放，从而提高其生物利用度，使 CBD 的给药在临床上更有效。
本文综述了有关大麻二酚先进传递系统（CBD-ADS）的科学报告，这些系统（i）已经开发，和（ii）已应用于治疗；包括截至 2020 年 1 月在主要科学数据库中发表的报告。没有实验数据和/或发表在英语以外语言的报告被排除在外。此外，还讨论了 CBD 治疗应用中的药物技术工具，强调了 CBD 载体使用的临床转化。
综述了报告 CBD-ADS 用于药用应用的研究，这些研究揭示了多方面的系统，可以克服 CBD 的物理化学缺点并提高其生物活性。因此，研究人员得出结论，开发的 CBD-ADS 可以替代传统制剂，因为它们在治疗方案中显示出相当或更高的疗效。尽管仍有一些标准需要满足，但我们的研究结果强调了 CBD-ADS 用于转化治疗的潜力，特别是在神经疾病方面。
